Skip to Content
Print Share

Generic Tekturna HCT Availability

Tekturna HCT is a brand name of aliskiren/hydrochlorothiazide, approved by the FDA in the following formulation(s):

TEKTURNA HCT (aliskiren hemifumarate; hydrochlorothiazide - tablet;oral)

  • Manufacturer: NODEN PHARMA
    Approval date: January 18, 2008
    Strength(s): EQ 150MG BASE;12.5MG [RLD], EQ 150MG BASE;25MG [RLD], EQ 300MG BASE;12.5MG [RLD], EQ 300MG BASE;25MG [RLD]

Has a generic version of Tekturna HCT been approved?

No. There is currently no therapeutically equivalent version of Tekturna HCT available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Tekturna HCT. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • .delta.-amino-.gamma.-hydroxy-.omega.-aryl-alkanoic acid amides
    Patent 5,559,111
    Issued: September 24, 1996
    Inventor(s): G oschke; Richard & Maibaum; J urgen K. & Schilling; Walter & Stutz; Stefan & Rigollier; Pascal & Yamaguchi; Yasuchika & Cohen; Nissim C. & Herold; Peter
    Assignee(s): Ciba-Geigy Corporation

    .delta.-Amino-.gamma.-hydroxy-.omega.-aryl-alkanoic acid amides of formula I ##STR1## and the salts thereof, have renin-inhibiting properties and can be used as antihypertensive medicinal active ingredients.

    Patent expiration dates:

    • July 21, 2018
      ✓ 
      Patent use: TREATMENT OF HYPERTENSION
      ✓ 
      Drug substance
      ✓ 
      Drug product
    • January 21, 2019
      ✓ 
      Pediatric exclusivity
  • Galenical formulations of organic compounds
    Patent 8,618,172
    Issued: December 31, 2013
    Assignee(s): Novartis AG

    The present invention relates to a solid oral dosage form comprising a therapeutically effective amount of aliskiren or a pharmaceutically acceptable salt thereof, a therapeutically effective amount of HCTZ and a hydrophilic filler selected from the group a carbohydrate or combinations thereof, e.g. sugars, sugar alcohols and starches or combinations of these.

    Patent expiration dates:

    • July 13, 2028
      ✓ 
      Drug product
  • Synergistic combinations comprising a renin inhibitor for cardiovascular diseases
    Patent 9,023,893
    Issued: May 5, 2015
    Assignee(s): Novartis AG

    The invention relates to a combination comprising the renin inhibitor of formula (I) or a pharmaceutically acceptable salt thereof.

    Patent expiration dates:

    • March 3, 2022
      ✓ 
      Drug product
Add to My Med List

More about Tekturna HCT (aliskiren / hydrochlorothiazide)

Consumer resources

Professional resources

Other Formulations

Related treatment guides

Glossary
TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.

Drugs.com Mobile Apps

The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. Available for Android and iOS devices.

Explore Apps
Hide